Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (2407)	4/19/2005 7:39:37 PM
From: zeta1961	Read Replies (1) \| Respond to of 12215

INGN still mine?..yeah..I've got a core and a trading position..Added again when it hit the 6's.. Tom, I'd recommend putting a sell for the 9-10 range to be safe..they still have some money in a shelf that they filed in August 2003..if past history informs, it's this range that's been the trigger for a secondary..a Zeta advice..very trepidly since, well, you know.. That said, they have some impressive lung cancer data in a small group of endstage cancer patients using their intravenous liposomal delivery of the FUS1 gene..a few survivors as long as 15 months(6 month life expectancy)..in last CC, they told us they'd be updating at ASCO.. Also updating on the mda7 gene that's in melanoma patients(Bernard/Jibacoa and the analysts like this one much more than advexin) Also data on their P1/P2 lung cancer vaccine(I personally have not put much into this one)..this abstract is the only one up at the ASCO site..I'm assuming that INGN would only present really good data at ASCO Big caveat..INGN is in the analyst dog house pending regulatory approval clarity for Advexin..Nance will not give them a crumb of priveleged info..I have no idea how this will play out during this season Now, I'm nervous.. Zeta